Compare GSK plc (GSK) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

PALL trades at $23.13, down 2.41% over 24 hours amid broader precious metals volatility. The technical outlook is bullish based on moving averages, with neutral oscillators suggesting potential consolidation. Recent news highlights palladium's underperformance relative to gold and silver, creating what some analysts view as a buying opportunity. The ETF underwent a 5-for-1 forward stock split effective May 18, 2026, which adjusted share count without changing the fund's total value.

The outlook for PALL hinges on palladium's supply-demand dynamics and industrial usage. While technical indicators suggest near-term strength, investors face risks from Federal Reserve policy uncertainty and fluctuating industrial demand. Analyst sentiment remains cautiously optimistic given the metal's significant price decline from recent highs, positioning the ETF for potential recovery if macroeconomic conditions stabilize.